Follicular eruptions are well-recognized adverse effects of epidermal growth factor receptor (EGFR) inhibitor therapy.1 Although alopecia is uncommon, mice with targeted disruption of the EGFR develop alopecia.2- 3 We report the development of scarring alopecia associated with use of the EGFR inhibitor gefitinib (Iressa; AstraZeneca, Mississisauga, Ontario, Canada).
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
A 70-year-old woman with marked frontal and vertex alopecia that appeared after the use of the epidermal growth factor receptor inhibitor gefitinib. Note the sharp demarcation of erythema at the frontal hair line and the presence of crusting (arrows).
Histologic images of punch biopsy specimens from the scalp vertex of the patient pictured in Figure 1. A, Mature anagen hairs are present in the subcutaneous fat, and loss of the superficial parts of the hair follicles is visible within the inflamed and scarred area. Note the superficial dermal edema (hematoxylin-eosin, original magnification ×50). Trichrome-Masson stain shows abundant collagen throughout the middle and deep dermis (inset) (original magnification ×20). B, High-power magnification of perifollicular infiltrate shows abundant plasma cells and fewer eosinophils and lymphocytes (hematoxylin-eosin, original magnification ×630).
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 12
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Register Now
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.